Actionable news
All posts from Actionable news
Actionable news in JAZZ: Jazz Pharmaceuticals plc,

Jazz Pharmaceuticals Is One Of The Most Attractive Biotech Stocks


Roughly, 70% of Jazz Pharmaceuticals' net product sales came from Xyrem, which is a treatment for Narcolepsy.

The company launched Defetelio in the U.S. in Spring 2016.

Xyrem still has room to grow.

JZP-110 appears to be a promising drug in the company's pipeline.

The recent Celator Pharmaceuticals acquisition fits in perfectly with the company's goals and...